CN110123776A - A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves - Google Patents
A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves Download PDFInfo
- Publication number
- CN110123776A CN110123776A CN201910413944.4A CN201910413944A CN110123776A CN 110123776 A CN110123776 A CN 110123776A CN 201910413944 A CN201910413944 A CN 201910413944A CN 110123776 A CN110123776 A CN 110123776A
- Authority
- CN
- China
- Prior art keywords
- parts
- calcium
- efficient
- microcirculation
- improves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 42
- 230000004089 microcirculation Effects 0.000 title claims abstract description 31
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000011575 calcium Substances 0.000 title claims abstract description 25
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 25
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 title claims abstract description 25
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 50
- 239000002994 raw material Substances 0.000 claims abstract description 33
- 239000011734 sodium Substances 0.000 claims abstract description 29
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 29
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 27
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical compound [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 claims abstract description 27
- 229960005438 calcium dobesilate Drugs 0.000 claims abstract description 27
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 27
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 25
- 229920000881 Modified starch Polymers 0.000 claims abstract description 24
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000001035 drying Methods 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 18
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 235000019441 ethanol Nutrition 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 235000020985 whole grains Nutrition 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- VNHHSBRJHXRDTE-UHFFFAOYSA-N benzenesulfonic acid;calcium Chemical compound [Ca].OS(=O)(=O)C1=CC=CC=C1 VNHHSBRJHXRDTE-UHFFFAOYSA-N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- -1 hydroxyl isomaltulose Chemical compound 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000004090 dissolution Methods 0.000 abstract description 6
- 229920002472 Starch Polymers 0.000 abstract description 5
- 239000008107 starch Substances 0.000 abstract description 5
- 235000019698 starch Nutrition 0.000 abstract description 5
- 230000003179 granulation Effects 0.000 abstract description 4
- 238000005469 granulation Methods 0.000 abstract description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000000853 adhesive Substances 0.000 abstract description 2
- 230000001070 adhesive effect Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of calcium hydrophenyl sulfonate capsules that efficient microcirculation improves, including following raw material: 50~60 parts of Calcium Dobesilate, 5~10 parts of pregelatinized starch, 5~10 parts of magnesium stearate, 10~15 parts of carboxycellulose sodium, 15~20 parts of ethanol water, 10~15 parts of sugar alcohol;The raw material specifically: 50 parts of Calcium Dobesilate, 5 parts of pregelatinized starch, 5 parts of magnesium stearate, 10 parts of carboxycellulose sodium, 20 parts of ethanol water, 10 parts of sugar alcohol.In the present invention, this simple formula composition such as more existing Calcium Dobesilate, sodium carboxymethyl starch and magnesium stearate, it joined the carboxy starch sodium and pregelatinized starch for being conducive to medicine disintegration and dissolution, pregelatinized starch is also used as adhesive that will be bonded together between raw material in the preparation simultaneously, to improve granulation efficiency, compared with traditional formula, takes the disintegration rate of rear drug in vivo and get a promotion with dissolution rate, more conducively absorption of drugs.
Description
Technical field
The invention belongs to pharmaceutical technology field, specially a kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves.
Background technique
Calcium Dobesilate is a kind of chemically synthesized capillary protection medicine, is developed by Di La Rand Corporation, Switzerland.
The medicine is introduced to the market in June, 2001 at home in loading " European Pharmacopoeia " in 1997, loading " British Pharmacopoeia " in 1998.In state
Just it is used to treat diabetes and the varication due to caused by microcirculation disorder, hemorrhoid from 1970s Calcium Dobesilate outside
Sore, myocardial infarction and pruritic dermatitis.In the higher area of living standard, aged people are to improve microcirculation and take for a long time
With, be acknowledged as prevent and treat microcirculation dysfunction, especially diabetic retinopathy unique matured product.
Research shows that Calcium Dobesilate can reduce wall of micrangium permeability, build up one's resistance to disease;Improve lymph reflux, reduces
Oedema;Blood viscosity is reduced, albumins/globulins ratio is corrected, the high aggregation of blood platelet is reduced, thus anti-tampon shape
At, and red blood cell flexibility is improved, it may also suppress vaso-active substance and high penetration caused by capilary acted on, reduce intravascular
Membrane damage improves the biosynthesis of basilar memebrane collagen.In addition, Calcium Dobesilate has apparent improvement to microcirculation disorder function
Effect, can enhance the activity of big blood vessel and microvascular endothelial cells nitric oxide synthetase, the capillary of antagonistic activity oxygen cluster
Permeability changes, to protect blood vessel;Can inhibit macrophage activating factor (MAF), hence it is evident that reduce macrophage adhesion thus have
Anti-inflammatory effect.
The current market orientation of Calcium Dobesilate is mainly based on diabetic retinopathy, but it is as a kind of novel blood
Protection of pipe agent, can also prevent and treat a variety of diseases as caused by microcirculation obstacle as: (1) caused by microcirculation disorder
The heart, brain, kidney diaseases (myocardial infarction, angina pectoris, thrombus sequela, atherosclerosis of renal glomerulus etc.);(2) blood viscosity is reduced;
(3) prevent microvascular corrosion cast;(4) numb limb, trick be ice-cold, pain, the diseases such as pruitus;(5) varication syndrome
Deng.With deepening continuously to diabetes and its chronic complicating diseases and ischemic Cardial or cerebral vascular diseases study on prevention, which has
Wide application prospect.
Calcium Dobesilate is clinically widely used at present, a large amount of clinical practices show Calcium Dobesilate be it is long-acting,
Safe and effective drug clinically has special pharmacological action and therapeutic effect, but the existing Calcium Dobesilate of existing market
Capsule is unfavorable for the storage and use of product, simultaneously since its process variations, capsule long-time stability cannot get larger improvement
After taking, the disintegration rate of drug in vivo and dissolution rate have greatly improved space.
Summary of the invention
It is an object of the invention to: storage and medicine disintegration dissolution rate in order to further enhance capsule provide one kind
The calcium hydrophenyl sulfonate capsule that efficient microcirculation improves.
The technical solution adopted by the invention is as follows:
A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, including following raw material: Calcium Dobesilate 50~
60 parts, 5~10 parts of pregelatinized starch, 5~10 parts of magnesium stearate, 10~15 parts of carboxycellulose sodium, ethanol water 15~20
Part, 10~15 parts of sugar alcohol;
Wherein, the raw material specifically: 50 parts of Calcium Dobesilate, 5 parts of pregelatinized starch, 5 parts of magnesium stearate, carboxyl is fine
Plain 10 parts of the sodium of dimension, 20 parts of ethanol water, 10 parts of sugar alcohol.
Wherein, it comprises the following steps that:
Step 1: Calcium Dobesilate being crossed into 80 meshes, carboxycellulose sodium sieves with 100 mesh sieve, and it is water-soluble to be then mixed into one third ethyl alcohol
In liquid, stir spare;
Step 2: pregelatinized starch and magnesium stearate being added in another one third ethanol water, stirred spare;
Step 3: sugar alcohol being added in another one third ethanol water, is stirred spare;
Step 4: raw material made from step 1 to 3 is stood into 20~30min;
Step 5: step 4 gains are subjected to whole grain by wobbler;
Step 6: particle is finally dried by drying machine;
Step 7: the particle filling after drying is packed into Capsules;
Step 8: sterilizing being carried out using ionising radiation, then carries out packaging finished product.
Wherein, the Capsules use 00# capsule.
Wherein, sterilization is added after step 7, sterilization is irradiated by ultraviolet radiator.
Wherein, preliminarily dried is added after step 4, the raw material after step 4 is stood is put into preliminarily dried in drying machine, does
45~50 DEG C of dry temperature, 20~25min of drying time.
Wherein, the carboxycellulose sodium is sodium carboxymethylcellulose.
Wherein, the sugar alcohol be D-sorbite, maltitol, xylitol, hydroxyl isomaltulose, mannitol, lactitol and
One or more of antierythrite.
Wherein, the sugar alcohol is xylitol.
In conclusion by adopting the above-described technical solution, the beneficial effects of the present invention are:
1, in the present invention, this simple formula composition such as more existing Calcium Dobesilate, sodium carboxymethyl starch and magnesium stearate,
It joined the carboxy starch sodium and pregelatinized starch for being conducive to medicine disintegration and dissolution, while pregelatinized starch is also used as adhesive
It will be bonded together between raw material in the preparation, to improve granulation efficiency, compared with traditional formula, take rear drug in body
Interior disintegration rate gets a promotion with dissolution rate, and more conducively absorption of drugs plays drug more effective, to micro-
Vascular treatment is more efficient.
2, in the present invention, by being mixed and being stood in batches each raw material with ethanol water, guarantee mutual energy
Enough sufficiently fusions ensure that the consistency of every particle drug content avoids to ensure the pharmacological property of capsule in granulation
The case where raw material mixing unevenness causes the influence of capsule pharmacological property amount unevenness to use.
3, in the present invention, the drying to raw material is carried out by preliminarily dried and final dry two step method, after preliminarily dried,
Raw material also has certain structural stability while with humidity, facilitates granulation, while the humidity in particle is by first one
Step is dried, then by finally drying, the humidity of particle can be made maximumlly to be dried, primary drying process is avoided
It is difficult to dry problem inside particle to occur, improves capsule storage capability.
Specific embodiment
In order to make the objectives, technical solutions, and advantages of the present invention clearer, the present invention is carried out below further
It is described in detail.It should be appreciated that described herein, specific examples are only used to explain the present invention, is not intended to limit the present invention.
Embodiment one, a kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, including following raw material: hydroxyl
50~60 parts of benzene sulfonic acid calcium, 5~10 parts of pregelatinized starch, 5~10 parts of magnesium stearate, 10~15 parts of carboxycellulose sodium, ethyl alcohol
15~20 parts of aqueous solution, 10~15 parts of sugar alcohol;
The raw material specifically: 50 parts of Calcium Dobesilate, 5 parts of pregelatinized starch, 5 parts of magnesium stearate, carboxycellulose
10 parts of sodium, 20 parts of ethanol water, 10 parts of sugar alcohol;
A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, comprises the following steps that:
Step 1: Calcium Dobesilate being crossed into 85 meshes, magnesium stearate and carboxycellulose sodium cross 90 meshes, spare;
Step 2: the raw material that step 1 is sieved is mixed with ethanol water, and pregelatinized starch is added while stirring, is made wet
Material;
Step 3: wet feed is stood into 10~15min;
Step 4: sugar alcohol being added in the wet feed after standing, is stirred evenly;
Step 5: step 4 gains are subjected to whole grain by wobbler;
Step 6: particle is dried by drying machine;
Step 7: the particle filling after drying is packed into Capsules;
Step 8: sterilizing being carried out using ionising radiation, then carries out packaging finished product.
Embodiment two, a kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, including following raw material: hydroxyl
50~60 parts of benzene sulfonic acid calcium, 5~10 parts of pregelatinized starch, 5~10 parts of magnesium stearate, 10~15 parts of carboxycellulose sodium, ethyl alcohol
15~20 parts of aqueous solution, 10~15 parts of sugar alcohol;
The raw material specifically: 50 parts of Calcium Dobesilate, 5 parts of pregelatinized starch, 5 parts of magnesium stearate, carboxycellulose
10 parts of sodium, 20 parts of ethanol water, 10 parts of sugar alcohol;
A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, comprises the following steps that:
Step 1: Calcium Dobesilate being crossed into 85 meshes, magnesium stearate and carboxycellulose sodium cross 90 meshes, spare;
Step 2: step 1 sieve raw material is mixed into the ethanol water of general component, uniform stirring;
Step: 3: the raw material of step 2 being mixed with the ethanol water of the other half component, pregelatinated is added while stirring and forms sediment
Wet feed is made in powder;
Step 4: wet feed being put into wobbler while sugar alcohol progress whole grain is added;
Step 5: particle is dried by drying machine;
Step 6: the particle filling after drying is packed into Capsules;
Step 8: sterilizing being carried out using ionising radiation, then carries out packaging finished product.
Embodiment three, a kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, including following raw material: hydroxyl
50~60 parts of benzene sulfonic acid calcium, 5~10 parts of pregelatinized starch, 5~10 parts of magnesium stearate, 10~15 parts of carboxycellulose sodium, ethyl alcohol
15~20 parts of aqueous solution, 10~15 parts of sugar alcohol;
The raw material specifically: 50 parts of Calcium Dobesilate, 5 parts of pregelatinized starch, 5 parts of magnesium stearate, carboxycellulose
10 parts of sodium, 20 parts of ethanol water, 10 parts of sugar alcohol;
A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, comprises the following steps that:
Step 1: Calcium Dobesilate being crossed into 80 meshes, magnesium stearate and carboxycellulose sodium cross 90 meshes, spare;
Step 2: the raw material that step 1 is sieved being mixed with the ethanol water of half component, pregelatinated is added while stirring and forms sediment
Wet feed is made in powder;
Step 3: wet feed is stood into 10~15min;
Step 4: the ethanol water of sugar alcohol and the other half component being added in the wet feed after standing, is stirred evenly;
Step 5: step 4 gains are subjected to whole grain by wobbler;
Step 6: particle is dried by drying machine;
Step 7: the particle filling after drying is packed into Capsules;
Step 8: sterilizing being carried out using ionising radiation, then carries out packaging finished product.
Example IV, a kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, including following raw material: hydroxyl
50~60 parts of benzene sulfonic acid calcium, 5~10 parts of pregelatinized starch, 5~10 parts of magnesium stearate, 10~15 parts of carboxycellulose sodium, ethyl alcohol
15~20 parts of aqueous solution, 10~15 parts of sugar alcohol;
The raw material specifically: 50 parts of Calcium Dobesilate, 5 parts of pregelatinized starch, 5 parts of magnesium stearate, carboxycellulose
10 parts of sodium, 20 parts of ethanol water, 10 parts of sugar alcohol;
A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, comprises the following steps that:
Step 1: Calcium Dobesilate being crossed into 85 meshes, magnesium stearate and carboxycellulose sodium cross 90 meshes, spare;
Step 2: sugar alcohol being poured into the ethanol water of one third component, stirred spare;
Step 3: by raw material that step 1 is sieved with another three/two-component ethanol water mixes, be added while stirring pre-
Wet feed is made in gelling starch;
Step 3: wet feed is stood into 10~15min;
Step 4: step 2 product and the wet feed after standing being mixed, and uniform stirring;
Step 5: step 4 gains are subjected to whole grain by wobbler;
Step 6: particle is dried by drying machine;
Step 7: the particle filling after drying is packed into Capsules;
Step 8: sterilizing being carried out using ionising radiation, then carries out packaging finished product.
Embodiment five, a kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, including following raw material: hydroxyl
50~60 parts of benzene sulfonic acid calcium, 5~10 parts of pregelatinized starch, 5~10 parts of magnesium stearate, 10~15 parts of carboxycellulose sodium, ethyl alcohol
15~20 parts of aqueous solution, 10~15 parts of sugar alcohol;
The raw material specifically: 50 parts of Calcium Dobesilate, 5 parts of pregelatinized starch, 5 parts of magnesium stearate, carboxycellulose
10 parts of sodium, 20 parts of ethanol water, 10 parts of sugar alcohol;
A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, comprises the following steps that:
Step 1: Calcium Dobesilate being crossed into 80 meshes, carboxycellulose sodium sieves with 100 mesh sieve, and it is water-soluble to be then mixed into one third ethyl alcohol
In liquid, stir spare;
Step 2: pregelatinized starch and magnesium stearate being added in one third ethanol water, stirred spare;
Step 3: sugar alcohol being added in one third ethanol water, is stirred spare;
Step 4: raw material made from step 1 to 3 is stood into 20~30min;
Step 5: the raw material after step 4 is stood is put into preliminarily dried in drying machine, and 45~50 DEG C of drying temperature, drying time 20
~25min
Step 6: step 5 gains are subjected to whole grain by wobbler;
Step 7: particle is finally dried by drying machine;
Step 8: the particle filling after drying is packed into Capsules;
Step 8: sterilizing being carried out using ionising radiation, then carries out packaging finished product.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Made any modifications, equivalent replacements, and improvements etc., should all be included in the protection scope of the present invention within mind and principle.
Claims (9)
1. a kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves, which is characterized in that including following raw material: hydroxyl
50~60 parts of benzene sulfonic acid calcium, 5~10 parts of pregelatinized starch, 5~10 parts of magnesium stearate, 10~15 parts of carboxycellulose sodium, ethyl alcohol
15~20 parts of aqueous solution, 10~15 parts of sugar alcohol.
2. the calcium hydrophenyl sulfonate capsule that a kind of efficient microcirculation as described in claim 1 improves, which is characterized in that described
Raw material specifically: 50 parts of Calcium Dobesilate, 5 parts of pregelatinized starch, 5 parts of magnesium stearate, 10 parts of carboxycellulose sodium, second
20 parts of alcohol solution, 10 parts of sugar alcohol.
3. the calcium hydrophenyl sulfonate capsule that a kind of efficient microcirculation as described in claim 1 improves, which is characterized in that including
Following making step:
Step 1: Calcium Dobesilate being crossed into 80 meshes, carboxycellulose sodium sieves with 100 mesh sieve, and it is water-soluble to be then mixed into one third ethyl alcohol
In liquid, stir spare;
Step 2: pregelatinized starch and magnesium stearate being added in another one third ethanol water, stirred spare;
Step 3: sugar alcohol being added in another one third ethanol water, is stirred spare;
Step 4: raw material made from step 1 to 3 is stood into 20~30min;
Step 5: step 4 gains are subjected to whole grain by wobbler;
Step 6: particle is finally dried by drying machine;
Step 7: the particle filling after drying is packed into Capsules;
Step 8: sterilizing being carried out using ionising radiation, then carries out packaging finished product.
4. the calcium hydrophenyl sulfonate capsule that a kind of efficient microcirculation as claimed in claim 3 improves, which is characterized in that described
Capsules use 00# capsule.
5. the calcium hydrophenyl sulfonate capsule that a kind of efficient microcirculation as claimed in claim 3 improves, which is characterized in that in step
Sterilization is added after rapid 7, sterilization is irradiated by ultraviolet radiator.
6. the calcium hydrophenyl sulfonate capsule that a kind of efficient microcirculation as claimed in claim 3 improves, which is characterized in that in step
Preliminarily dried is added after rapid 4, the raw material after step 4 is stood is put into preliminarily dried in drying machine, 45~50 DEG C of drying temperature, does
Dry 20~25min of time.
7. the calcium hydrophenyl sulfonate capsule that a kind of efficient microcirculation as described in claim 1 improves, which is characterized in that described
Carboxycellulose sodium is sodium carboxymethylcellulose.
8. the calcium hydrophenyl sulfonate capsule that a kind of efficient microcirculation as described in claim 1 improves, which is characterized in that described
Sugar alcohol be one of D-sorbite, maltitol, xylitol, hydroxyl isomaltulose, mannitol, lactitol and antierythrite or
It is several.
9. the calcium hydrophenyl sulfonate capsule that a kind of efficient microcirculation as claimed in claim 8 improves, which is characterized in that described
Sugar alcohol is xylitol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910413944.4A CN110123776A (en) | 2019-05-17 | 2019-05-17 | A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910413944.4A CN110123776A (en) | 2019-05-17 | 2019-05-17 | A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110123776A true CN110123776A (en) | 2019-08-16 |
Family
ID=67575098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910413944.4A Pending CN110123776A (en) | 2019-05-17 | 2019-05-17 | A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110123776A (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147112A (en) * | 1996-04-03 | 2000-11-14 | Laboratorios Del Dr. Esteve, S.A. | Use of 2,5-dihydroxybenzenesulfonic derivatives for the normalization of endothelial function |
CN102091055A (en) * | 2011-01-28 | 2011-06-15 | 海南锦瑞制药股份有限公司 | Calcium dobesilate capsule and preparation method thereof |
CN102579396A (en) * | 2012-04-01 | 2012-07-18 | 宁夏康亚药业有限公司 | Calcium dobesilate capsule composition |
US20130172414A1 (en) * | 2010-06-29 | 2013-07-04 | Tianjin Nankai Share Pharmaceutical Science & Technology Co., Ltd. | Pharmaceutical composition comprising levocarnitine and dobesilate |
CN103230383A (en) * | 2013-03-31 | 2013-08-07 | 北京万全阳光医学技术有限公司 | Calcium dobesilate capsule composition and preparation method thereof |
CN104434873A (en) * | 2014-11-18 | 2015-03-25 | 成都医路康医学技术服务有限公司 | Calcium dobesilate capsule |
CN106619564A (en) * | 2016-12-23 | 2017-05-10 | 北京满格医药科技有限公司 | Calcium dobesilate capsule and preparation method |
-
2019
- 2019-05-17 CN CN201910413944.4A patent/CN110123776A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147112A (en) * | 1996-04-03 | 2000-11-14 | Laboratorios Del Dr. Esteve, S.A. | Use of 2,5-dihydroxybenzenesulfonic derivatives for the normalization of endothelial function |
US20130172414A1 (en) * | 2010-06-29 | 2013-07-04 | Tianjin Nankai Share Pharmaceutical Science & Technology Co., Ltd. | Pharmaceutical composition comprising levocarnitine and dobesilate |
CN102091055A (en) * | 2011-01-28 | 2011-06-15 | 海南锦瑞制药股份有限公司 | Calcium dobesilate capsule and preparation method thereof |
CN102579396A (en) * | 2012-04-01 | 2012-07-18 | 宁夏康亚药业有限公司 | Calcium dobesilate capsule composition |
CN103230383A (en) * | 2013-03-31 | 2013-08-07 | 北京万全阳光医学技术有限公司 | Calcium dobesilate capsule composition and preparation method thereof |
CN104434873A (en) * | 2014-11-18 | 2015-03-25 | 成都医路康医学技术服务有限公司 | Calcium dobesilate capsule |
CN106619564A (en) * | 2016-12-23 | 2017-05-10 | 北京满格医药科技有限公司 | Calcium dobesilate capsule and preparation method |
Non-Patent Citations (2)
Title |
---|
刘辉等: "预胶化淀粉对羟苯磺酸钙胶囊溶出度的影响", 《中国药房》 * |
郑建仙 主编: "《功能性食品学(第二版)》", 30 June 2009 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104902874A (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
CN103191077B (en) | Gliclazide tablet and preparation method thereof | |
CN101623269A (en) | Oral sustained release granules | |
CN101766582A (en) | Levamlodipine beaylate tablets and preparation method thereof | |
CN101444503A (en) | Efficient long-acting silibinin preparation and preparation method thereof | |
CN110123776A (en) | A kind of calcium hydrophenyl sulfonate capsule that efficient microcirculation improves | |
CN101700248A (en) | A kind of preparation method of ascator enteric-coated sustained-release capsule | |
CN101390844B (en) | Arginine ibuprofen tablet and preparation method thereof | |
CN100335134C (en) | Nimodipine soft capsule and its prepn | |
CN107868009B (en) | Metoprolol tartrate crystal, pharmaceutical composition containing metoprolol tartrate crystal and preparation method of pharmaceutical composition | |
CN113456607B (en) | Sacubitril valsartan sodium monolayer osmotic pump controlled release tablet and preparation method thereof | |
CN101773482B (en) | Three-stage pulsed release controlled release tablet and preparation method thereof | |
CN1123344C (en) | Slowly releasing piperazine ferulate | |
CN102028660B (en) | Gliclazide oral sustained-release dry-mixed suspension and preparation method thereof | |
CN107441055A (en) | A kind of preparation method of controlled release drug | |
CN107050419A (en) | A kind of osmotic pump tablet of Perindopril and its salt and preparation method thereof | |
JP2012522024A (en) | Levorotating amlodipine combination drug composition | |
CN102125559B (en) | A kind of pharmaceutical composition containing pentoxifylline and sodium carbosulfonate and its pharmaceutical use | |
CN101879169A (en) | Compound preparation for treating relevant vascular diseases and preparation method thereof | |
CN114681422A (en) | A kind of nifedipine controlled-release tablet and preparation method thereof | |
CN104758273A (en) | Urea micro-capsule preparation and preparation method thereof | |
US20080194560A1 (en) | Disintegration promoters in solid dose wet granulation formulations | |
CN103494816B (en) | A kind of pharmaceutical composition for treating diabetes | |
CN101606922B (en) | Glucosamine potassium sulfate microcapsule and preparation method and application thereof | |
CN102327277B (en) | Fosinopril sodium and hydrochlorothiazide pharmaceutical composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190816 |
|
RJ01 | Rejection of invention patent application after publication |